GIP and diabetes mellitus: These findings demonstrated tirzepatide’s neuroprotective properties against the pathophysiology of cognitive impairment brought on by DM, and they also raised the possibility that GIP/GLP-1 receptors would be a useful therapeutic target for avoiding the central nervous system difficulties brought on by DM.